Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for biomarkers to personalize head and neck cancer treatment

NCT ID NCT07211139

Knowledge-focused Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is analyzing blood and tumor samples from 30 people with advanced head and neck cancer who are receiving standard immunotherapy plus chemotherapy. The goal is to find biological markers that can predict who will respond well to treatment. By understanding changes in the tumor and immune system, researchers hope to develop more personalized treatment strategies in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
immune checkpoint inhibitors and cytotoxic chemotherapy
What this could lead to
If successful, this could help doctors identify which head and neck cancer patients are most likely to benefit from immunotherapy, leading to more personalized and effective treatment plans.
What could go wrong
This is a small, early-stage exploratory study with only 30 participants, so results may not apply to all patients. It focuses on understanding biomarkers rather than testing a new treatment, so direct patient benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with recurrent or metastatic head and neck squamous cell carcinoma treated at Samsung Medical Center. Approximately 600 patients with head and neck cancer visit the center annually, and more than 50 patients are newly diagnosed with recurrent/metastatic disease and receive systemic therapy each year. This study will recruit eligible patients from this population.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) * Received first-line combination therapy with immune checkpoint inhibitor and cytotoxic chemotherapy * Availability of tumor tissue samples at Samsung Medical Center * p16 and PD-L1 expression status evaluable within the institution * Age ≥ 20 years * Ability to understand the study purpose and provide written informed consent Exclusion Criteria: * Not meeting the inclusion criteria * Considered ineligible for enrollment at the discretion of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Samsung Medical Center

    RECRUITING

    Seoul, Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.